14 Most Undervalued NASDAQ Stocks to Buy Now

Page 10 of 14

5. Gilead Sciences, Inc. (NASDAQ:GILD)

Forward P/E Ratio as of September 20: 13.24

Number of Hedge Fund Holders: 71

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of Yeztugo, the first HIV prevention twice-yearly subcutaneous injectable.

According to Moody’s, Gilead’s liver and cancer platforms have a solid position for future expansion, especially with drugs like Livdelzi and Trodelvy.

Moreover, the firm identified governance risk concerns as a major factor in the rating update, indicating a favorable assessment of management’s financial strategy and credibility. In recent years, Gilead Sciences, Inc. (NASDAQ:GILD) has upheld conservative financial practices, concentrating on bolt-on acquisitions under $5 billion.

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S. biopharmaceutical company headquartered in Foster City, California, focuses on developing antiviral treatments for illnesses such as COVID-19, hepatitis B and C, influenza, and HIV/AIDS.

Page 10 of 14